Univariate analysis for CIR (censored for SCT)
| Variable . | Events/N (%) . | Median (mo) . | HR (95% confidence interval) . | P value . |
|---|---|---|---|---|
| Age, continuous, y | 188 of 635 (29.6) | 23.7 | 1.00 (0.99-1.01) | .879 |
| Age, categorical, y | ||||
| <60 | 96 of 338 (28.4) | 20.0 | 1.00 | — |
| ≥60 | 92 of 297 (31.0) | 26.2 | 0.92 (0.69-1.22) | .575 |
| Sex | ||||
| Male | 104 of 323 (32.2) | 30.6 | 1.00 | — |
| Female | 84 of 312 (26.9) | 20.0 | 0.93 (0.70-1.23) | .597 |
| Treatment intensity | ||||
| IA | 106 of 385 (27.5) | 29.5 | 1.00 | — |
| LOW + VEN | 82 of 250 (32.8) | 19.2 | 1.05 (0.79-1.40) | .742 |
| Best response | ||||
| CR | 141 of 534 (26.4) | 35.7 | 1.00 | — |
| CRi | 36 of 76 (47.4) | 5.7 | 2.42 (1.65-3.55) | < .001 |
| MLFS | 11 of 25 (44.0) | 3.6 | 2.33 (1.08-5.02) | .031 |
| MRD status | ||||
| Negative | 101 of 426 (23.7) | 55.9 | 1.00 | — |
| Positive | 87 of 209 (41.6) | 7.3 | 2.39 (1.79-3.18) | < .001 |
| ELN 2017 risk | ||||
| Favorable | 28 of 161 (17.4) | 64.2 | 1.00 | — |
| Intermediate | 56 of 190 (29.5) | 29.5 | 2.18 (1.44-3.32) | < .001 |
| Adverse | 101 of 273 (37.0) | 8.3 | 3.49 (2.36-5.17) | < .001 |
| Cytogenetics∗ | ||||
| Diploid | 69 of 307 (22.5) | 55.9 | 1.00 | — |
| Other intermediate | 28 of 100 (28.0) | 16.4 | 1.45 (0.93-2.26) | .097 |
| 11q23 | 12 of 34 (35.3) | 4.4 | 4.21 (2.02-8.76) | < .001 |
| t(6;9) | 2 of 8 (25.0) | 14.4 | 2.24 (0.57-8.75) | .246 |
| inv(3) | 7 of 10 (70.0) | 2.9 | 7.59 (2.69-21.41) | < .001 |
| −5/5q– | 38 of 76 (50.0) | 5.8 | 3.53 (2.28-5.45) | < .001 |
| −7/7q– | 30 of 70 (42.9) | 5.8 | 3.22 (2.01-5.17) | < .001 |
| −17/17p– | 27 of 52 (51.9) | 5.3 | 4.10 (2.48-6.79) | < .001 |
| Complex | 65 of 136 (47.8) | 5.8 | 3.51 (2.48-4.97) | < .001 |
| Variable . | Events/N (%) . | Median (mo) . | HR (95% confidence interval) . | P value . |
|---|---|---|---|---|
| Age, continuous, y | 188 of 635 (29.6) | 23.7 | 1.00 (0.99-1.01) | .879 |
| Age, categorical, y | ||||
| <60 | 96 of 338 (28.4) | 20.0 | 1.00 | — |
| ≥60 | 92 of 297 (31.0) | 26.2 | 0.92 (0.69-1.22) | .575 |
| Sex | ||||
| Male | 104 of 323 (32.2) | 30.6 | 1.00 | — |
| Female | 84 of 312 (26.9) | 20.0 | 0.93 (0.70-1.23) | .597 |
| Treatment intensity | ||||
| IA | 106 of 385 (27.5) | 29.5 | 1.00 | — |
| LOW + VEN | 82 of 250 (32.8) | 19.2 | 1.05 (0.79-1.40) | .742 |
| Best response | ||||
| CR | 141 of 534 (26.4) | 35.7 | 1.00 | — |
| CRi | 36 of 76 (47.4) | 5.7 | 2.42 (1.65-3.55) | < .001 |
| MLFS | 11 of 25 (44.0) | 3.6 | 2.33 (1.08-5.02) | .031 |
| MRD status | ||||
| Negative | 101 of 426 (23.7) | 55.9 | 1.00 | — |
| Positive | 87 of 209 (41.6) | 7.3 | 2.39 (1.79-3.18) | < .001 |
| ELN 2017 risk | ||||
| Favorable | 28 of 161 (17.4) | 64.2 | 1.00 | — |
| Intermediate | 56 of 190 (29.5) | 29.5 | 2.18 (1.44-3.32) | < .001 |
| Adverse | 101 of 273 (37.0) | 8.3 | 3.49 (2.36-5.17) | < .001 |
| Cytogenetics∗ | ||||
| Diploid | 69 of 307 (22.5) | 55.9 | 1.00 | — |
| Other intermediate | 28 of 100 (28.0) | 16.4 | 1.45 (0.93-2.26) | .097 |
| 11q23 | 12 of 34 (35.3) | 4.4 | 4.21 (2.02-8.76) | < .001 |
| t(6;9) | 2 of 8 (25.0) | 14.4 | 2.24 (0.57-8.75) | .246 |
| inv(3) | 7 of 10 (70.0) | 2.9 | 7.59 (2.69-21.41) | < .001 |
| −5/5q– | 38 of 76 (50.0) | 5.8 | 3.53 (2.28-5.45) | < .001 |
| −7/7q– | 30 of 70 (42.9) | 5.8 | 3.22 (2.01-5.17) | < .001 |
| −17/17p– | 27 of 52 (51.9) | 5.3 | 4.10 (2.48-6.79) | < .001 |
| Complex | 65 of 136 (47.8) | 5.8 | 3.51 (2.48-4.97) | < .001 |
HRs are for individual cytogenetic features compared to diploid as the baseline risk.